Mesoblast Stock Analysis
MESO Stock | USD 5.11 0.10 2.00% |
Mesoblast is undervalued with Real Value of 5.89 and Target Price of 6.83. The main objective of Mesoblast stock analysis is to determine its intrinsic value, which is an estimate of what Mesoblast is worth, separate from its market price. There are two main types of Mesoblast's stock analysis: fundamental analysis and technical analysis. Fundamental analysis focuses on the financial and economic factors that affect Mesoblast's performance, such as revenue growth, earnings, and financial stability. Technical analysis, on the other hand, focuses on the price and volume data of Mesoblast's stock to identify patterns and trends that may indicate its future price movements.
The Mesoblast stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Mesoblast is usually not traded on Thanksgiving Day, Christmas Day, New Year 's Day, Dr . Martin Luther King Jr 's Birthday, Washington 's Birthday, Good Friday, Memorial Day, Juneteenth Holiday, Independence Day, Labour Day. Mesoblast Stock trading window is adjusted to America/New York timezone. Here, you can get updates on important government artifacts, including earning estimates, SEC corporate filings, announcements, and Mesoblast's ongoing operational relationships across important fundamental and technical indicators.
Mesoblast |
Mesoblast Stock Analysis Notes
The company has price-to-book ratio of 1.07. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Mesoblast recorded a loss per share of 0.87. The entity had not issued any dividends in recent years. The firm had 1:2 split on the 10th of January 2024. Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, the United Kingdom, and Switzerland. Mesoblast Limited was incorporated in 2004 and is headquartered in Melbourne, Australia. Mesoblast operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 77 people. To find out more about Mesoblast contact Silviu Itescu at 61 3 9639 6036 or learn more at https://www.mesoblast.com.Mesoblast Quarterly Total Revenue |
|
Mesoblast Investment Alerts
Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Mesoblast's investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Mesoblast or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
Mesoblast is way too risky over 90 days horizon | |
Mesoblast appears to be risky and price may revert if volatility continues | |
The company reported the previous year's revenue of 7.5 M. Net Loss for the year was (81.89 M) with loss before overhead, payroll, taxes, and interest of (47.42 M). | |
Mesoblast currently holds about 85.5 M in cash with (63.27 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.62. | |
Mesoblast has a poor financial position based on the latest SEC disclosures | |
Latest headline from investing.com: Australia stocks lower at close of trade SPASX 200 down 0.09 |
Mesoblast Upcoming and Recent Events
Earnings reports are used by Mesoblast to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Mesoblast previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
26th of February 2024 Upcoming Quarterly Report | View | |
23rd of May 2024 Next Financial Report | View | |
31st of December 2023 Next Fiscal Quarter End | View | |
4th of September 2024 Next Fiscal Year End | View | |
30th of September 2023 Last Quarter Report | View | |
30th of June 2023 Last Financial Announcement | View |
Mesoblast Largest EPS Surprises
Earnings surprises can significantly impact Mesoblast's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
---|---|---|---|---|---|---|---|
2023-02-27 | 2022-12-31 | -0.1802 | -0.1574 | 0.0228 | 12 | ||
2022-05-31 | 2022-03-31 | -0.13 | -0.16 | -0.03 | 23 | ||
2020-05-27 | 2020-03-31 | -0.17 | -0.14 | 0.03 | 17 |
Mesoblast Thematic Classifications
In addition to having Mesoblast stock in your portfolios, you can add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your favorite investment opportunity, you can then obtain an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility. If you are a result-oriented investor, you can benefit from optimizing one of our existing themes to build an efficient portfolio against your specific investing outlook.
Cancer FightersPublic companies from health care and pharmaceutical sectors that are focused on fighting cancer |
Mesoblast Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Mesoblast is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Mesoblast backward and forwards among themselves. Mesoblast's institutional investor refers to the entity that pools money to purchase Mesoblast's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Shares | Rhumbline Advisers | 2023-09-30 | 17.3 K | Chapin Davis Inc | 2023-09-30 | 17 K | Lpl Financial Corp | 2023-09-30 | 12.9 K | Diligent Investors, Llc | 2023-09-30 | 12.5 K | Aries Wealth Management | 2023-09-30 | 10 K | Blue Zone Wealth Advisors, Llc | 2023-09-30 | 10 K | Institutional & Family Asset Management, Llc | 2023-09-30 | 3 K | Compagnie Lombard, Odier Sca | 2023-09-30 | 2 K | Gamma Investing Llc | 2023-12-31 | 690 | Penbrook Management Llc | 2023-12-31 | 275.4 K | Susquehanna International Group, Llp | 2023-09-30 | 92.4 K |
Mesoblast Market Capitalization
The company currently falls under 'Small-Cap' category with a current market capitalization of 582.9 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Mesoblast's market, we take the total number of its shares issued and multiply it by Mesoblast's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.Mesoblast Profitablity
Mesoblast's profitability indicators refer to fundamental financial ratios that showcase Mesoblast's ability to generate income relative to its revenue or operating costs. If, let's say, Mesoblast is currently losing money, the management's focus should be on how to reverse that trend. However, when revenue exceeds expenses, Mesoblast's executives or investors may be in less hurry to break that information down - which is where profitability analysis comes into play. Gaining a greater understanding of Mesoblast's profitability requires more research than a typical breakdown of Mesoblast's financial statements. By doing a profitability analysis, companies can identify areas needing attention, and investors can make a profitable trade.
Last Reported | Projected for Next Year | ||
Return On Tangible Assets | (1.02) | (1.07) | |
Return On Capital Employed | (0.1) | (0.10) | |
Return On Assets | (0.11) | (0.12) | |
Return On Equity | (0.16) | (0.15) |
Management Efficiency
Mesoblast has return on total asset (ROA) of (0.0561) % which means that it has lost $0.0561 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.1449) %, meaning that it created substantial loss on money invested by shareholders. Mesoblast's management efficiency ratios could be used to measure how well Mesoblast manages its routine affairs as well as how well it operates its assets and liabilities. As of the 19th of April 2024, Return On Tangible Assets is likely to drop to -1.07. In addition to that, Return On Capital Employed is likely to drop to -0.1. At this time, Mesoblast's Other Current Assets are very stable compared to the past year. As of the 19th of April 2024, Total Current Assets is likely to grow to about 117.6 M, while Total Assets are likely to drop about 575 M.Last Reported | Projected for Next Year | ||
Book Value Per Share | 5.79 | 4.92 | |
Net Current Asset Value | 0.00 | 0.00 | |
Tangible Asset Value | 0.00 | 0.00 | |
Tangible Book Value Per Share | (1.11) | (1.06) | |
Enterprise Value Over EBITDA | (9.07) | (9.52) | |
Price Book Value Ratio | 1.40 | 1.33 | |
Enterprise Value Multiple | (9.07) | (9.52) | |
Price Fair Value | 1.40 | 1.33 | |
Enterprise Value | 589.6 M | 1.1 B |
The analysis of Mesoblast's management efficiency is an essential part of evaluating and assessing the financial and operational performance of the entity. It is also vital to analyze Mesoblast's future growth prospects and the overall market conditions to determine the value and potential of its stock. The analysis involves studying a range of financial metrics such as revenue, earnings, profit margins, cash flow, debt, market share, and external factors such as economic trends, industry outlook, competition, and government regulations. The goal of Mesoblast Stock analysis is to determine whether it is undervalued, fairly valued, or overvalued and to make informed investment decisions.
Beta 2.593 |
Technical Drivers
As of the 19th of April, Mesoblast secures the Mean Deviation of 5.99, downside deviation of 4.57, and Risk Adjusted Performance of 0.1163. In connection with fundamental indicators, the technical analysis model lets you check existing technical drivers of Mesoblast, as well as the relationship between them. Strictly speaking, you can use this information to find out if the firm will indeed mirror its model of past prices, or the prices will eventually revert. We are able to interpolate and collect nineteen technical drivers for Mesoblast, which can be compared to its peers in the industry. Please verify Mesoblast information ratio, potential upside, as well as the relationship between the Potential Upside and kurtosis to decide if Mesoblast is priced some-what accurately, providing market reflects its recent price of 5.11 per share. Given that Mesoblast has jensen alpha of 2.05, we recommend you to check Mesoblast's last-minute market performance to make sure the company can sustain itself at a future point.Mesoblast Price Movement Analysis
Incorrect Input. Please change your parameters or increase the time horizon required for running this function. The output start index for this execution was zero with a total number of output elements of zero. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. Mesoblast middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for Mesoblast. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.
Mesoblast Predictive Daily Indicators
Mesoblast intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Mesoblast stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Mesoblast Corporate Filings
6K | 17th of April 2024 A report filed by foreign private issuers with SEC. A foreign private issuer is a non-U.S. company with securities traded on U.S. exchanges. | ViewVerify |
16th of April 2024 Other Reports | ViewVerify | |
13A | 9th of April 2024 An amended filing to the original Schedule 13G | ViewVerify |
13A | 3rd of April 2024 An amended filing to the original Schedule 13G | ViewVerify |
6K | 27th of March 2024 A report filed by foreign private issuers with SEC. A foreign private issuer is a non-U.S. company with securities traded on U.S. exchanges. | ViewVerify |
6K | 21st of March 2024 A report filed by foreign private issuers with SEC. A foreign private issuer is a non-U.S. company with securities traded on U.S. exchanges. | ViewVerify |
13A | 20th of March 2024 An amended filing to the original Schedule 13G | ViewVerify |
6K | 15th of March 2024 A report filed by foreign private issuers with SEC. A foreign private issuer is a non-U.S. company with securities traded on U.S. exchanges. | ViewVerify |
Mesoblast Forecast Models
Mesoblast's time-series forecasting models are one of many Mesoblast's stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Mesoblast's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.About Mesoblast Stock Analysis
Stock analysis is the technique used by a trader or investor to examine and evaluate how Mesoblast prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Mesoblast shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Mesoblast. By using and applying Mesoblast Stock analysis, traders can create a robust methodology for identifying Mesoblast entry and exit points for their positions.
Last Reported | Projected for Next Year | ||
Pretax Profit Margin | (9.85) | (10.34) | |
Operating Profit Margin | (8.30) | (8.71) | |
Net Loss | (9.83) | (10.32) | |
Gross Profit Margin | (3.10) | (2.95) |
Current Mesoblast Analysis - Recommendations
We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Mesoblast analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Mesoblast analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target Price | Advice | # of Analysts | |
6.83 | Buy | 3 | Odds |
Most Mesoblast analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Mesoblast stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Mesoblast, talking to its executives and customers, or listening to Mesoblast conference calls.
Mesoblast Stock Analysis Indicators
Mesoblast stock analysis indicators help investors evaluate how Mesoblast stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Mesoblast shares will generate the highest return on investment. By understating and applying Mesoblast stock analysis, traders can identify Mesoblast position entry and exit signals to maximize returns.
Begin Period Cash Flow | 60.4 M | |
Long Term Debt | 102.8 M | |
Common Stock Shares Outstanding | 77.9 M | |
Total Stockholder Equity | 501.8 M | |
Total Cashflows From Investing Activities | -194 K | |
Tax Provision | -212 K | |
Property Plant And Equipment Net | 6.5 M | |
Cash And Short Term Investments | 70.9 M | |
Cash | 70.9 M | |
Accounts Payable | 20.1 M | |
Net Debt | 45.6 M | |
50 Day M A | 3.1822 | |
Total Current Liabilities | 42 M | |
Other Operating Expenses | 76.8 M | |
Non Current Assets Total | 587.8 M | |
Forward Price Earnings | 833.3333 | |
Non Currrent Assets Other | 481 K | |
Stock Based Compensation | 3.7 M |
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Mesoblast. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in state. To learn how to invest in Mesoblast Stock, please use our How to Invest in Mesoblast guide.You can also try the Funds Screener module to find actively-traded funds from around the world traded on over 30 global exchanges.
Complementary Tools for Mesoblast Stock analysis
When running Mesoblast's price analysis, check to measure Mesoblast's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Mesoblast is operating at the current time. Most of Mesoblast's value examination focuses on studying past and present price action to predict the probability of Mesoblast's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Mesoblast's price. Additionally, you may evaluate how the addition of Mesoblast to your portfolios can decrease your overall portfolio volatility.
Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
Fundamental Analysis View fundamental data based on most recent published financial statements | |
Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments |
Is Mesoblast's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Mesoblast. If investors know Mesoblast will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Mesoblast listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.87) | Revenue Per Share 0.09 | Quarterly Revenue Growth (0.12) | Return On Assets (0.06) | Return On Equity (0.14) |
The market value of Mesoblast is measured differently than its book value, which is the value of Mesoblast that is recorded on the company's balance sheet. Investors also form their own opinion of Mesoblast's value that differs from its market value or its book value, called intrinsic value, which is Mesoblast's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Mesoblast's market value can be influenced by many factors that don't directly affect Mesoblast's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Mesoblast's value and its price as these two are different measures arrived at by different means. Investors typically determine if Mesoblast is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Mesoblast's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.